(Total Views: 559)
Posted On: 07/15/2019 3:19:04 PM
Post# of 416
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints Dr. Peter Novak to Scientific Advisory Board
Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist and autonomic specialist who serves as the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. In addition, he is a member of the American Academy of Neurology, the American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board,” Endonovo CEO Alan Collier stated in the news release. “Peter’s experience will add significant value to our oversight as we transition to and advance our differentiated development programs in Electroceuticals(TM). We also welcome the insights of Dr. Novak, whose expertise in key areas relating to our programs will inform both our clinical and post-operative strategies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(TM) therapeutic devices, this morning announced its appointment of Peter Novak, M.D., Ph.D., to its scientific advisory board. According to the update, Novak is a board-certified neurologist and autonomic specialist who serves as the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. In addition, he is a member of the American Academy of Neurology, the American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. “The Endonovo team is delighted to welcome Dr. Novak to the Scientific Board,” Endonovo CEO Alan Collier stated in the news release. “Peter’s experience will add significant value to our oversight as we transition to and advance our differentiated development programs in Electroceuticals(TM). We also welcome the insights of Dr. Novak, whose expertise in key areas relating to our programs will inform both our clinical and post-operative strategies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
